Shenzhen Weiguang Biological Products Co., Ltd. (SHE:002880)
China · Delayed Price · Currency is CNY 26.51
+0.42 (1.61%)
May 12, 2026, 3:04 PM CST
SHE:002880 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 1,264 | 1,267 | 1,193 | 1,020 | 659.82 | 894.22 |
Other Revenue | - | - | 10.54 | 28.96 | 8.12 | 13.21 |
| 1,264 | 1,267 | 1,203 | 1,049 | 667.93 | 907.43 | |
Revenue Growth (YoY) | 5.13% | 5.27% | 14.75% | 56.98% | -26.39% | 0.32% |
Cost of Revenue | 773.7 | 768.05 | 699.32 | 615.26 | 427.02 | 536.52 |
Gross Profit | 489.83 | 498.61 | 503.87 | 433.24 | 240.91 | 370.91 |
Selling, General & Admin | 131.41 | 131.12 | 121.81 | 126.94 | 91.67 | 88.45 |
Research & Development | 45.59 | 46.02 | 49.05 | 63.62 | 35.87 | 47.59 |
Other Operating Expenses | -1.71 | -2.53 | 5.16 | 3.25 | -1.73 | 7.36 |
Operating Expenses | 175.29 | 174.61 | 180.1 | 191.31 | 124.47 | 144.51 |
Operating Income | 314.54 | 324 | 323.76 | 241.93 | 116.44 | 226.4 |
Interest Expense | - | - | -21.93 | -14.34 | -2.06 | -1.87 |
Interest & Investment Income | 4.19 | 3.77 | 7.92 | 8.03 | 8.85 | 8.91 |
Other Non Operating Income (Expenses) | -51.43 | -46.62 | -1.81 | -0.94 | -1.62 | -1.15 |
EBT Excluding Unusual Items | 267.3 | 281.15 | 307.95 | 234.68 | 121.62 | 232.29 |
Gain (Loss) on Sale of Investments | 1.87 | 1.87 | -14.05 | 2.23 | 14.33 | 0.74 |
Gain (Loss) on Sale of Assets | - | - | 0.21 | 0.06 | 0.04 | - |
Asset Writedown | - | - | -0.06 | -0.16 | -0.5 | - |
Other Unusual Items | - | - | 2.69 | 8.65 | 1.84 | 8.15 |
Pretax Income | 269.17 | 283.02 | 296.74 | 245.45 | 137.32 | 241.17 |
Income Tax Expense | 36.33 | 37.23 | 42.78 | 27.91 | 16.1 | 36.18 |
Earnings From Continuing Operations | 232.84 | 245.79 | 253.96 | 217.54 | 121.21 | 204.99 |
Minority Interest in Earnings | 0.7 | 0.53 | -0.44 | 1.11 | -3.69 | 0.44 |
Net Income | 233.54 | 246.32 | 253.52 | 218.65 | 117.52 | 205.44 |
Net Income to Common | 233.54 | 246.32 | 253.52 | 218.65 | 117.52 | 205.44 |
Net Income Growth | -6.75% | -2.84% | 15.95% | 86.06% | -42.80% | 7.90% |
Shares Outstanding (Basic) | 227 | 227 | 227 | 227 | 227 | 227 |
Shares Outstanding (Diluted) | 227 | 227 | 227 | 227 | 227 | 227 |
Shares Change (YoY) | 0.00% | -0.00% | 0.00% | 0.01% | -0.01% | 0.00% |
EPS (Basic) | 1.03 | 1.09 | 1.12 | 0.96 | 0.52 | 0.91 |
EPS (Diluted) | 1.03 | 1.09 | 1.12 | 0.96 | 0.52 | 0.91 |
EPS Growth | -6.76% | -2.84% | 15.94% | 86.05% | -42.79% | 7.90% |
Free Cash Flow | -39.92 | 93.49 | -77.73 | 69.08 | -326.17 | 6.06 |
Free Cash Flow Per Share | -0.18 | 0.41 | -0.34 | 0.30 | -1.44 | 0.03 |
Dividend Per Share | - | - | 0.200 | 0.400 | - | 0.200 |
Dividend Growth | - | - | -50.00% | - | - | 11.98% |
Gross Margin | 38.77% | 39.36% | 41.88% | 41.32% | 36.07% | 40.88% |
Operating Margin | 24.89% | 25.58% | 26.91% | 23.07% | 17.43% | 24.95% |
Profit Margin | 18.48% | 19.45% | 21.07% | 20.85% | 17.59% | 22.64% |
Free Cash Flow Margin | -3.16% | 7.38% | -6.46% | 6.59% | -48.83% | 0.67% |
EBITDA | 477.36 | 477.39 | 439.43 | 328.19 | 180.64 | 280.85 |
EBITDA Margin | 37.78% | 37.69% | 36.52% | 31.30% | 27.05% | 30.95% |
D&A For EBITDA | 162.82 | 153.39 | 115.67 | 86.26 | 64.2 | 54.45 |
EBIT | 314.54 | 324 | 323.76 | 241.93 | 116.44 | 226.4 |
EBIT Margin | 24.89% | 25.58% | 26.91% | 23.07% | 17.43% | 24.95% |
Effective Tax Rate | 13.50% | 13.15% | 14.42% | 11.37% | 11.73% | 15.00% |
Revenue as Reported | - | - | 1,203 | 1,049 | 667.93 | 907.43 |
Advertising Expenses | - | - | 0.31 | 0.45 | 0.28 | 0.18 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.